The Molecular Adapter SLP-76 Relays Signals from Platelet Integrin alpha IIbbeta 3 to the Actin Cytoskeleton*

Achim ObergfellDagger , Barbi A. Judd§, Miguel A. del PozoDagger , Martin A. SchwartzDagger , Gary A. Koretzky§, and Sanford J. ShattilDagger ||**

From the Departments of Dagger  Vascular Biology and || Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California 92037 and the Graduate Program in Immunology, the § Signal Transduction Program, Leonard and Madlyn Abramson Family Cancer Research Institute, and the  Department of Pathology and Laboratory Medicine, the University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104

Received for publication, November 26, 2000



    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Platelet adhesion to fibrinogen through integrin alpha IIbbeta 3 triggers actin rearrangements and cell spreading. Mice deficient in the SLP-76 adapter molecule bleed excessively, and their platelets spread poorly on fibrinogen. Here we used human platelets and a Chinese hamster ovary (CHO) cell expression system to better define the role of SLP-76 in alpha IIbbeta 3 signaling. CHO cell adhesion to fibrinogen required alpha IIbbeta 3 and stimulated tyrosine phosphorylation of SLP-76. SLP-76 phosphorylation required coexpression of Syk tyrosine kinase and stimulated association of SLP-76 with the adapter, Nck, and with the Rac exchange factor, Vav1. SLP-76 expression increased lamellipodia formation induced by Syk and Vav1 in adherent CHO cells (p < 0.001). Although lamellipodia formation requires Rac, SLP-76 functioned downstream of Rac by potentiating adhesion-dependent activation of PAK kinase (p < 0.001), a Rac effector that associates with Nck. In platelets, adhesion to fibrinogen stimulated the association of SLP-76 with the SLAP-130 adapter and with VASP, a SLAP-130 binding partner implicated in actin reorganization. Furthermore, SLAP-130 colocalized with VASP at the periphery of spread platelets. Thus, SLP-76 functions to relay signals from alpha IIbbeta 3 to effectors of cytoskeletal reorganization. Therefore, deficient recruitment of specific adapters and effectors to sites of adhesion may explain the integrin phenotype of SLP-76-/- platelets.



    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Integrins were originally identified as adhesion receptors for extracellular matrix proteins (ECM),1 but these alpha beta transmembrane heterodimers also transmit information into the cell. This process, referred to as "outside-in signaling," promotes anchorage-dependent cellular responses including motility, growth, differentiation, and survival (1). Most integrin alpha  and beta  cytoplasmic tails consist of 20-70 amino acid residues and are devoid of enzymatic activity, implying that outside-in signals are transmitted by integrin-associated proteins. Several transmembrane proteins can interact with the extracellular domains of integrins, but attention has focused on proteins that interact with integrin cytoplasmic tails (2, 3). These include alpha -actinin and talin, cytoskeletal proteins that link integrins to actin filaments (4). Cell attachment to the ECM causes lateral clustering of integrin heterodimers into oligomers and evidence is accumulating that outside-in signaling is triggered, in part, by the co-clustering of integrin-associated adapters, enzymes and substrates into signaling complexes that localize within and modify the actin cytoskeleton (1, 4, 5). This model is directly relevant to integrin alpha IIbbeta 3 signaling in blood platelets.

alpha IIbbeta 3 is a receptor for fibrinogen and von Willebrand factor that mediates platelet aggregation and spreading on vascular ECM (6). These responses are accompanied by major changes in platelet morphology and in organization of the actin cytoskeleton. For example, platelet attachment to fibrinogen or von Willebrand factor is accompanied by progressive actin polymerization, filopodial and lamellipodial extension, and eventually full spreading (7-9). Recent work has identified at least three sets of signaling responses triggered by ligand binding to alpha IIbbeta 3 that potentially mediate these changes. One, detectable within seconds of cell attachment, involves tyrosine phosphorylation and activation of the Syk protein tyrosine kinase (10). The others are detectable only after 30-120 s and involve tyrosine phosphorylation and activation of the FAK tyrosine kinase and tyrosine phosphorylation of the integrin beta 3 tail (11, 12). In sharp contrast to phosphorylation of FAK and beta 3, Syk phosphorylation and activation are unaffected by blockade of actin filament barbed ends by cytochalasin D, suggesting that actin polymerization is not required. In fact, two of the most prominent Syk substrates in platelets, Vav1 and SLP-76, may function to promote actin polymerization downstream of alpha IIbbeta 3.

Vav1 is an hematopoietic cell-specific guanine nucleotide exchange factor for cdc42 and Rac (13). The GTP-bound forms of cdc42 and Rac promote filopodial and lamellipodial extension, respectively (14). SLP-76, the focus of the present work, is an hematopoietic cell-specific adapter protein that contains an N-terminal SAM domain, several potential tyrosine phosphorylation sites, a central proline-rich region and a C-terminal SH2 domain (Fig. 1). Studies in lymphoid cells indicate that three phosphotyrosines in SLP-76 (Y113, Y128, and Y145) are required for interactions with the SH2 domains of Vav1 and Nck (15, 16). Of potential relevance to alpha IIbbeta 3 signaling, Nck is an adapter that can influence cytoskeletal events by recruiting a Rac effector, the PAK1 serine-threonine kinase, to plasma membrane adhesion sites (17). The proline-rich region of SLP-76 interacts with the SH3 domain of Gads, a Grb2-like adapter (18). The SH2 domain of SLP-76 interacts with tyrosine-phosphorylated SLAP-130 (19, 20), an adapter that can bind in turn through an FP4 polyproline motif to the EVH1 domain of VASP, an actin-binding protein implicated in regulating actin polymerization within lamellipodia and focal adhesions (4, 21, 22). Because all of these SLP-76 binding partners are present in platelets, SLP-76 might be in a pivotal position to transmit alpha IIbbeta 3 signals to the cytoskeleton. Consistent with this hypothesis, SLP-76-deficient mice exhibit a bleeding diathesis and defects in platelet function, including reduced spreading on fibrinogen. Retroviral reconstitution of SLP-76-/- bone marrow cells with SLP-76 corrects these platelet defects (23).



View larger version (26K):
[in this window]
[in a new window]
 
Fig. 1.   Domain structure of SLP-76. Portions of SLP-76 that interact directly with Vav1, Nck, Gads, and SLAP-130 are indicated. The numbers orient the reader to the approximate location of domains in the linear sequence. Arrows point to potential effectors of Vav1, Nck, and SLAP-130 that are evaluated in this study.

Based on these considerations, the present study was carried out to determine more precisely the role of SLP-76 in outside-in alpha IIbbeta 3 signaling. Using a CHO cell model system and human platelets, we show here that SLP-76 becomes tyrosine-phosphorylated in fibrinogen-adherent cells in an alpha IIbbeta 3 and Syk-dependent manner. Furthermore, SLP-76 enhances lamellipodia formation triggered by an outside-in signaling pathway that involves alpha IIbbeta 3, Syk, Vav, and Rac. Whereas SLP-76 does not affect Rac activation, it does enhance adhesion-dependent activation of PAK. Moreover, through its interactions with SLAP-130, SLP-76 may help to localize VASP to alpha IIbbeta 3 adhesion sites at the edges of spreading platelets. Thus, SLP-76 functions to relay signals from alpha IIbbeta 3 to actin.


    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Reagents-- Monoclonal antibodies: anti-Syk (4D10) was from Santa Cruz Biotechnology Inc. (Santa Cruz, CA); anti-phosphotyrosine (4G10 and PY20) from Upstate Biotechnology (Lake Placid, NY) and Transduction Laboratories (Lexington, KY), respectively; anti-VASP from ImmunoGlobe GmbH, Grobeta ostheim, Germany; anti-Vav, anti-FLAG M2 and anti-Rac from Upstate Biotechnology; and anti-LIBS6 Fab, an integrin beta 3 activating antibody, was a gift from Mark Ginsberg (Scripps). Rabbit polyclonal antibody to Nck (5547) was a gift from David Schlaepfer (Scripps Research Institute). Polyclonal anti-PAK1 antibody was described previously (24). Sheep polyclonal antibodies to SLP-76 and SLAP-130 were described previously (25). Horseradish peroxidase-conjugated secondary antibodies were from Bio-Rad Laboratories (Hercules, CA). Cy-5-conjugated anti-mouse and anti-sheep IgG were from Jackson ImmunoResearch Laboratories Inc. (West Grove, PA); fluorescein isothiocyanate-conjugated anti-mouse IgG was from BIOSOURCE International Inc. (Camarillo, CA). Rhodamine-phalloidin was from Molecular Probes (Eugene, OR), purified human fibrinogen from Enzyme Research Laboratories Inc. (South Bend, IN), bovine serum albumin and sodium orthovanadate from Fisher. Protein A and Protein G-Sepharose were from Amersham Pharmacia Biotech (Piscataway, NJ), glutathione-agarose and leupeptin from Sigma, Pefabloc and aprotinin from Roche Molecular Biochemicals (Indianapolis, IN), and LipofectAMINE from Life Technologies, Inc.

Cell Culture, Plasmids, and Transfections-- A5 CHO cells, which stably express alpha IIbbeta 3, were maintained in complete Dulbecco's modified Eagle's medium containing 10% fetal calf serum (26). The following mammalian expression plasmids were used: pEMCV/Syk and pEF/Myc-Vav1 (27); pSAP/CD8-gamma (a chimera containing the extracellular and transmembrane domain of CD8 fused to the cytoplasmic domain of the gamma  subunit of Fcepsilon R1, Ref. 28); pcDNA3/HA-Rac1 (24); and pEF/FLAG-SLP-76 (wild-type and mutants) (15). Subconfluent cells in 100 mm dishes were transfected with up to 4 µg of plasmid DNA using LipofectAMINE according to the manufacturer's instructions. When necessary, pcDNA3 was added to maintain equal amounts of DNA in all transfections. Twenty-four hours later, the concentration of fetal calf serum was lowered from 10 to 0.5%, and cells were cultured for an additional 24 h before use in functional assays.

CHO Cell Binding to Fibrinogen-- A5 cell transfectants were resuspended using trypsin-EDTA, washed twice with Dulbecco's modified Eagle's medium, resuspended to 3 × 106 cells/ml in Dulbecco's modified Eagle's medium, and incubated for 45 min with 20 µM cyclohexamide. To test the effects of binding of soluble fibrinogen to alpha IIbbeta 3, cells were incubated for an additional 15 min with 250 µg/ml fibrinogen, in the presence or absence of 0.5 mM MnCl2 (to activate integrins) or 10 µM Integrilin or 0.5 mM EDTA (to inhibit ligand binding to alpha IIbbeta 3) (29). Cells were then washed with phosphate-buffered saline, lysed for 10 min in ice-cold RIPA buffer containing 1 mM sodium vanadate, 0.5 Mm leupeptin, 0.25 mg/ml Pefabloc, and 5 µg/ml aprotinin, clarified by sedimentation in a microcentrifuge, and subjected to immunoprecipitation and Western blotting (27, 28). For studies of cells adherent to fibrinogen, bacterial tissue culture plates were precoated with 5 mg/ml bovine serum albumin (BSA) or 100 µg/ml fibrinogen. After blocking for 2 h at room temperature with heat-denatured BSA, 4.5 × 106 cells in 1.5 ml were added to each plate and incubated for 45 min at 37 °C in a CO2 incubator. After 60 min, nonadherent cells from the BSA plates were sedimented at 14,000 rpm for 3 s in a microcentrifuge and lysed immediately in RIPA buffer. Cells adherent to fibrinogen were rinsed twice in phosphate-buffered saline, lysed on the plates directly, and then processed for immunoprecipitation and Western blotting. When coprecipitation of two or more proteins was being assessed, the cells were lysed in buffer containing 0.5% Nonidet P-40, 150 mM NaCl, 50 mM Tris, pH 7.4, and inhibitors.

Immunoprecipitation and Western Blotting-- Equal amounts of each lysate, typically 250-500 µg of protein in 500 µl, were immunoprecipitated with the indicated antibodies, subjected to electrophoresis on 7.5% SDS-polyacrylamide gels, and transferred onto nitrocellulose (27, 28). Membranes were blocked with 3% nonfat dry milk and probed with the indicated primary and horseradish peroxidase-conjugated secondary antibodies. Immunoreactive bands were detected by enhanced chemiluminescence. Blots were scanned in a Hewlett-Packard ScanJet 5300C scanner, and labeled bands were quantified by calibrated densitometry using NIH Image software.

Rac GTPase and PAK Kinase Assays-- Endogenous PAK was immunoprecipitated from Nonidet P-40 lysates and PAK kinase activity was determined using an in gel kinase assay with myelin basic protein as substrate (24). Active Rac was monitored using a pull-down assay involving a recombinant fragment of PAK that binds specifically to Rac-GTP (24).

Confocal Microscopy-- Twenty-four hours after CHO cell transfection, cells were plated on coverslips coated with 100 µg/ml fibrinogen and incubated in the presence of 0.5% fetal calf serum for an additional 18 h at 37 °C in a CO2 incubator. Adherent cells were then fixed in 3.7% formaldehyde, permeabilized with 0.1% Triton X-100, and stained with primary antibodies to transfected proteins, secondary antibodies conjugated with fluorescein isothiocyanate or Cy5, and rhodamine-phalloidin to stain F-actin. Lamellipodia formation in fibrinogen-adherent cells was quantified using an MRC 1024 Bio-Rad laser scanning confocal imaging system and expressed as the percentage of cells that contained one or more lamellipodium (27). Scoring was carried out in a blinded fashion by two independent observers, and at least 100 transfected cells were examined for every transfection combination in each experiment. Digital images were prepared using Adobe Photoshop, version 5.5.

Platelet Studies-- Fresh whole blood was obtained from normal volunteers, anticoagulated with ACD, and washed platelets were prepared (8). To enable soluble fibrinogen to bind to alpha IIbbeta 3, platelets were resuspended to 3.5 × 108/ml and incubated for 5 min at 37 °C with 250 µg/ml fibrinogen in the presence of the beta 3 activating antibody, LIBS-6 Fab (150 µg/ml). As a control, parallel samples were incubated in the presence of Ro 43-5054 (10 µM), a selective alpha IIbbeta 3 antagonist that blocks fibrinogen binding (30). To study the effects of adhesion to fibrinogen, platelets were incubated in fibrinogen-coated or BSA-coated dishes in the presence of 2 units/ml apyrase for 30 min (31). Then cells adherent to fibrinogen or suspended over BSA were lysed in Nonidet P-40 buffer, the lysates were immunoprecipitated with antibodies to SLP-76 or SLAP-130, and Western blots were probed with antibodies to phosphotyrosine, SLP-76, SLAP-130, or VASP (23). For confocal microscopy, cells were plated onto fibrinogen-coated coverslips at 107/ml for 45 min at 37 °C in the presence or absence of 200 nM phorbol myristate acetate (PMA) to enhance spreading. Platelets were fixed, permeabilized, stained with antibodies to SLAP-130 and VASP, and examined by confocal microscopy (8).


    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

alpha IIbbeta 3 Signals to SLP-76-- In platelets, fibrinogen binding to alpha IIbbeta 3 leads to rapid tyrosine phosphorylation of SLP-76 (23). To study the mechanisms and consequences of integrin signaling to SLP-76, this adapter was transiently expressed in A5 CHO cells, which stably express alpha IIbbeta 3. To determine whether alpha IIbbeta 3 signals to SLP-76 in CHO cells as in platelets, A5 cells were first incubated with soluble fibrinogen in the presence of 0.5 mM MnCl2, an extrinsic activator of integrins (32). Despite successful ectopic expression of SLP-76, no tyrosine phosphorylation of SLP-76 was observed. In contrast, if SLP-76 was cotransfected with Syk, there was now a marked increase in tyrosine phosphorylation of SLP-76 when fibrinogen binding was induced by MnCl2 (Fig. 2A). This response as well as the tyrosine phosphorylation of Syk itself were inhibited by compounds that block fibrinogen binding to alpha IIbbeta 3, including the selective alpha IIbbeta 3 antagonist, Integrilin, and the divalent cation chelator, EDTA. In the experiment shown in Fig. 2A, fibrinogen binding was carried out for 15 min, but similar results were obtained at 30 s, the earliest time point tested. Identical results were obtained if fibrinogen binding was induced by a beta 3-specific-activating antibody, anti-LIBS6 Fab, instead of MnCl2 (not shown). In addition, tyrosine phosphorylation of SLP-76 was observed when cells were plated on immobilized fibrinogen, even in the presence of 10 µM cytochalasin D, an inhibitor of actin polymerization (Fig. 2B). As previously observed (27), cytochalasin D blocked alpha IIbbeta 3-dependent tyrosine phosphorylation and activation of FAK but not Syk. These results indicate that SLP-76 is situated downstream of alpha IIbbeta 3 and Syk in a signaling pathway that becomes activated by fibrinogen binding, independent of actin polymerization.



View larger version (46K):
[in this window]
[in a new window]
 
Fig. 2.   alpha IIbbeta 3-dependent tyrosine phosphorylation of SLP-76 in CHO cells. A, A5 CHO cells were transfected with cDNAs for SLP-76 and/or Syk, as indicated. Forty-eight hours later, fibrinogen binding to alpha IIbbeta 3 was stimulated by 0.5 mM MnCl2 as described under "Experimental Procedures." Some studies were carried out in the presence of 10 µM Integrilin or 5 mM EDTA, which inhibits fibrinogen binding to alpha IIbbeta 3. Syk and SLP-76 were then immunoprecipitated from RIPA lysates and subjected to Western blotting with anti-phosphotyrosine antibodies. Blots were reprobed with antibodies to Syk and SLP-76 to assess loading of each lane. B, A5 cells transfected with Syk and SLP-76 were plated onto dishes coated with fibrinogen or BSA, either in the presence of 10 µM cytochalasin D (CD) or Me2SO control vehicle. After 45 min at 37 °C, adherent cells on the fibrinogen plates and nonadherent cells in the BSA plates were lysed in RIPA and immunoprecipitated with an antibody to SLP-76 or FAK. Western blots were probed with anti-phosphotyrosine antibodies and reprobed with antibodies to SLP-76 or FAK. C, A5 cells were transfected with Syk and either wild-type SLP-76 (WT) or SLP-76 (Y113F, Y128F, Y145F), referred to as 3Yright-arrowF. Then the effect of cell adhesion to fibrinogen on tyrosine phosphorylation of SLP-76 was studied. To compare these results with SLP-76 phosphorylation mediated by an ITAM-dependent mechanism, some cells were cotransfected with Syk, SLP-76, and CD8gamma and then maintained in suspension over BSA for 45 min at 37 °C before immunoprecipitation and Western blotting. D, A5 cells were transfected with Syk and the indicated SLP-76 deletion mutant, and alpha IIbbeta 3-dependent SLP-76 tyrosine phosphorylation was studied. For clarity, SLP-76 and its mutants have been placed next to each other, although on the original gels each migrated as expected according its molecular size. Data shown are representative of three experiments.

In antigen-stimulated T cells, SLP-76 phosphorylation is dependent on signals generated through T cell receptor subunits that bear ITAM motifs, and it is abolished by phenylalanine substitution of SLP-76 tyrosines 113, 128, and 145 (SLP-76-(3Yright-arrowF), see Ref. 15). To evaluate whether these tyrosine residues are involved in alpha IIbbeta 3 signaling, SLP-76-(3Yright-arrowF) was expressed with Syk in A5 CHO cells. Despite levels of expression similar to wild-type SLP-76, adhesion-dependent tyrosine phosphorylation of SLP-76-(3Yright-arrowF) was reduced by an average of 66% (three experiments). Under the same conditions, tyrosine-phosphorylation of SLP-76-(3Yright-arrowF) induced by overexpression of an ITAM-bearing CD8gamma chimera was virtually abolished (Fig. 2C). In addition, adhesion-dependent tyrosine phosphorylation was still observed with a SLP-76 truncation mutant consisting of the N-terminal half of the molecule (amino acids 1-266) but not with SLP-76-(1-266)-(3Yright-arrowF) or with a mutant consisting of SLP-76 residues 157-533 (Fig. 2D). Thus, SLP-76 tyrosine residues 113, 128, and/or 145 are major targets of Syk-dependent phosphorylation during outside-in alpha IIbbeta 3 signaling. However, in contrast to ITAM-based signaling, one or more additional tyrosines in SLP-76 are phosphorylated in response to integrin ligation.

SLP-76 Enhances Lamellipodia Formation during alpha IIbbeta 3-dependent Cell Adhesion-- SLP-76-deficient mouse platelets exhibit reduced spreading on fibrinogen (23). One early event during spreading is lamellipodia formation, a response that involves alpha IIbbeta 3, Syk, Vav1 and Rac (27, 33). Because SLP-76 is situated downstream of alpha IIbbeta 3 and Syk, we asked whether SLP-76 expression affected the formation of lamellipodia. Twenty-four hours after transfection of Syk, Vav1, and SLP-76, A5 cells were plated on fibrinogen-coated coverslips for another 18 h and then examined by confocal microscopy. Identification of cells expressing the recombinant proteins was accomplished by three color fluorescence analysis, as shown in Fig. 3A. As observed previously (27), the percentage of fibrinogen-adherent CHO cells that exhibited one or more lamellipodium was greatly increased by coexpression of Syk and Vav1, and this response was dependent on the amount of Vav1 expressed (Fig. 3B). Even in the presence of Syk alone however, SLP-76 caused a modest but consistent increase in lamellipodia formation (p < 0.03), and the enhancing effect of SLP-76 was maintained in the presence of Vav1 (p < 0.003, Fig. 3B).



View larger version (36K):
[in this window]
[in a new window]
 
Fig. 3.   Effect of Syk, Vav-1, and SLP-76 on lamellipodia formation in fibrinogen adherent A5 CHO cells. Cells were transfected as indicated with Syk, Vav1 (low, 0.075 µg/plate; high, 1 µg/plate), wild-type SLP-76 or SLP-76 mutants. After 24 h, the cells were plated on fibrinogen-coated coverslips and 18 h later fixed, permeabilized, and stained with rhodamine-phalloidin to mark F-actin (red). Simultaneously, anti-Vav1 antibody and fluorescein isothiocyanate-conjugated second antibody were used to assess expression of Vav1 (green), and anti-FLAG antibody and Cy5 s antibody were used to assess SLP-76 (blue). Panel A contains representative images that document the degree of expression of Vav1 and wild-type SLP-76; arrowheads point to lamellipodia. In panel B, lamellipodia were quantified in a blind fashion by two independent observers and expressed as the percentage of cells that contained one or more lamellipodium. Data represent mean ± S.E. of 3-14 independent experiments. p values were derived by Student's t test for paired data.

Because tyrosine-phosphorylated SLP-76 can bind directly to the SH2 domain of Vav1, we wondered if this interaction was necessary for the SLP-76 effect on lamellipodia. In the SLP-76-(3Yright-arrowF) mutant, the tyrosines needed for interaction with Vav1 (or Nck) are not present (15, 16). Indeed, unlike the case for wild-type SLP-76, Vav1, and Nck were not observed in SLP-76-(3Yright-arrowF) immunoprecipitates from fibrinogen-adherent A5 cells (Fig. 4). Despite this, SLP-76-(3Yright-arrowF) was fully able to enhance lamellipodia formation induced by Syk and Vav1 (Fig. 3B). Moreover, a SLP-76 deletion mutant (Delta 224-244) that lacks the polyproline binding site for Gads and a mutant (R448K) that abrogates the SLP-76 SH2 interaction with SLAP-130 (34) were similarly able to enhance lamellipodia formation (Fig. 3B). On the other hand, SLP-76 truncation mutants containing either the N-terminal half () or the C-terminal half () of the molecule failed to support lamellipodia formation (Fig. 3B). Taken together, these results indicate that one function of SLP-76 is to enhance lamellipodia formation during alpha IIbbeta 3 signaling. Furthermore, at least when ectopically expressed, the loss of any single known adapter function of SLP-76 does not prevent this effect.



View larger version (57K):
[in this window]
[in a new window]
 
Fig. 4.   Effect of alpha IIbbeta 3-dependent cell adhesion to fibrinogen on the association of SLP-76 with Vav1 and Nck. A5 cells were transfected with Syk, Vav1, and wild-type SLP-76 or SLP-76-(3Yright-arrowF) and plated on fibrinogen or BSA dishes as described in the Fig. 2 legend. After 45 min at 37 °C, cells were lysed in Nonidet P-40 lysis buffer, lysates were immunoprecipitated with antibody to SLP-76, and Western blots were probed for phosphotyrosine, Vav1, SLP-76, or Nck. Data shown are representative of three experiments.

Downstream Effectors of SLP-76 in alpha IIbbeta 3 Signaling-- Lamellipodial extension involves actin polymerization in localized regions of the cortical cytoskeleton. Because SLP-76 is a multivalent adapter, it has the potential to influence the subcellular localization or function of several proteins that have been implicated in regulating cytoskeletal dynamics. We focused attention on three such proteins, Rac, PAK, and VASP. Rac promotes actin polymerization and lamellipodial extension in many cell types, including platelets and A5 CHO cells (27, 35, 36). In platelets, Rac may be activated to its GTP-bound form by Vav1 (37). Because the Rac exchange activity of Vav1 increases following its tyrosine phosphorylation (13, 38, 39), we examined whether SLP-76 expression influenced tyrosine phosphorylation of Vav1 or levels of Rac-GTP. In A5 cells cotransfected with Syk and Vav1, tyrosine phosphorylation of Vav1 increased 4-fold 30-45 min after cell adhesion to fibrinogen, and cotransfection of SLP-76 had no effect on this response (not shown). Moreover, although levels of Rac-GTP increased 10-fold upon adhesion of Syk/Vav1 transfectants to fibrinogen, SLP-76 did not alter this response (Fig. 5). Thus, although SLP-76 enhances a Rac-dependent lamellipodial response triggered by alpha IIbbeta 3, it does not do so by activating Rac. This suggests that SLP-76 functions downstream of Rac and/or independent of it.



View larger version (37K):
[in this window]
[in a new window]
 
Fig. 5.   Effect of SLP-76 on alpha IIbbeta 3-dependent activation of Rac. A5 cells were transfected with epitope-tagged Rac and as indicated with Syk, Vav1, and SLP-76. After plating on fibrinogen or BSA dishes, Rac activity was assessed by quantifying Rac-GTP by a pull-down assay. A, results from a single experiment where bound Rac is equivalent to Rac-GTP. B, gel band intensities for Rac-GTP and total Rac were quantified by densitometry. Rac activity was taken as the ratio of Rac-GTP/total Rac and arbitrarily expressed as percent of the activity observed for the fibrinogen-adherent Syk/Vav1/SLP-76 transfectants. Data represent the mean ± S.E. of three independent experiments. Not shown is the fact that adhesion-dependent Rac activity for the Syk/Vav transfectants represented 57% of maximal activity observed with constitutively active Rac V12.

Because wild-type SLP-76 interacted with Nck in fibrinogen-adherent A5 cells (Fig. 4), we asked whether SLP-76 expression increased the activity of PAK, a Nck-binding partner and Rac effector (17). In the presence of Syk and Vav1, adhesion of A5 cells to fibrinogen stimulated more than a 3-fold increase in PAK activity (p < 0.01). However, in the presence of SLP-76, adhesion-dependent PAK activity increased more than 10-fold (p < 0.01) (Fig. 6, A and C). On the other hand, expression of SLP-76-(3Yright-arrowF) had no effect on PAK activity, consistent with a requirement for an interaction between SLP-76 and Nck for this response to take place (Fig. 6, B and C). Thus, one effect of wild-type SLP-76 in alpha IIbbeta 3 signaling is to increase the activity of PAK. However, the results with the SLP-76-(3Yright-arrowF) mutant indicate that this effect is not essential for enhancement of lamellipodia formation, at least when SLP-76-(3Yright-arrowF) is ectopically expressed (Fig. 3B).



View larger version (31K):
[in this window]
[in a new window]
 
Fig. 6.   Effect of SLP-76 on alpha IIbbeta 3-dependent activation of PAK. A5 cells were transfected as indicated with Syk, Vav1, and SLP-76, then plated on fibrinogen or BSA dishes. PAK activity was measured by in gel kinase assay. A, results from a single experiment with wild-type SLP-76. B, second experiment comparing wild-type SLP-76 with SLP-76-(3Yright-arrowF). C, gel band intensities for PAK activity were quantified by densitometry, normalized for total immunoprecipitated PAK, and expressed as a percent of the activity observed for the fibrinogen-adherent Syk/Vav1/SLP-76 transfectants. Data represent the mean ± S.E. of three independent experiments.

VASP is a prominent phosphoprotein in platelets (40), and it may interact directly with SLAP-130 in lymphoid cells (22). Therefore, we asked if there was any relationship between SLP-76, SLAP-130, and VASP during outside-in alpha IIbbeta 3 signaling in platelets. Human platelets were incubated with soluble fibrinogen in the presence or absence of the LIBS-6 Fab beta 3-activating antibody. Then Nonidet P-40 cell lysates were immunoprecipitated with antibodies to SLP-76 or SLAP-130. Western blots of SLP-76 immunoprecipitates revealed a prominent 130 kDa tyrosine-phosphorylated band that comigrated with SLAP-130 (Fig. 7A). Fibrinogen binding to the platelets in response to LIBS-6 Fab caused an increase in tyrosine phosphorylation of this band as well as of SLP-76, and this response was inhibited by RO 43-5054, a selective alpha IIbbeta 3 antagonist (30). Similar results were obtained if lysates were immunoprecipitated with SLAP-130 instead of SLP-76 (Fig. 7B). In both cases, the binding of soluble fibrinogen to the platelets caused little or no increase in the amount of SLAP-130 that coimmunoprecipitated with SLP-76, suggesting that the main effect of alpha IIbbeta 3 ligation under these conditions was on tyrosine phosphorylation of these adapters (Fig. 7, A and B). Thus, SLP-76 and SLAP-130 interact in platelets and their states of tyrosine phosphorylation are modulated by outside-in signaling through alpha IIbbeta 3.



View larger version (56K):
[in this window]
[in a new window]
 
Fig. 7.   Effect of fibrinogen binding to alpha IIbbeta 3 on tyrosine phosphorylation of SLP-76 and SLAP-130 in human platelets. Washed platelets were incubated without stirring for 5 min at 37 °C with 250 µg/ml fibrinogen (lane 1), fibrinogen + 150 µg/ml anti-LIBS6 Fab (lane 2), fibrinogen + anti-LIBS6 Fab + 10 µM Ro 43-5054 (lane 3), or 10 µg/ml collagen (lane 4). Nonidet P-40 lysates were immunoprecipiated with antibodies to SLP-76 or SLAP-130, and Western blots were probed with antibodies to phosphotyrosine, SLP-76, and SLAP-130. Data shown are representative of three experiments.

For SLAP-130 and VASP to play a coordinate role in alpha IIbbeta 3-dependent platelet spreading, it would be predicted that they interact with each other and localize within lamellae at the platelet periphery. To assess the subcellular localization of SLAP-130 and VASP, platelets were allowed to attach to fibrinogen-coated coverslips for 45 min in the presence or absence of PMA, the latter added to enhance actin-rich lamellae and spreading (8). Under these conditions, a portion of total cellular SLAP-130 and VASP colocalized to a rim at the edges of the spread platelets (Fig. 8A). SLP-76 localization could not be evaluated because our antibodies are not suitable for immunofluorescence. To determine whether SLAP-130 and SLP-76 form a physical complex with VASP, platelets were allowed to adhere to fibrinogen for 30 min, and Nonidet P-40 lysates were immunoprecipitated with an antibody to SLAP-130 or SLP-76. VASP could be detected in SLAP-130 and SLP-76 immunoprecipitates from fibrinogen-adherent platelets, but there was substantially less VASP in immunoprecipitates from nonadherent platelets (Fig. 8B). These results indicate that platelet adhesion to fibrinogen promotes formation of a multimolecular complex involving SLP-76, SLAP-130, and VASP. They suggest that one function of SLP-76 in alpha IIbbeta 3 signaling may be to recruit SLAP-130 and VASP to adhesion sites at the edges of spreading platelets.



View larger version (47K):
[in this window]
[in a new window]
 
Fig. 8.   SLAP-130 and VASP interactions in human platelets. A, platelets were incubated for 45 min on fibrinogen-coated coverslips in the presence or absence of 200 nM PMA. Adherent cells were then fixed, permeabilized, and stained with antibodies to SLAP-130 and VASP (green and red, respectively, in the merged images). The yellow rim staining in the merged images indicates partial colocalization of these proteins to the periphery of fibrinogen-adherent platelets. Bar = 10 µm. B, washed platelets were maintained in suspension or plated on fibrinogen for 30 min. Then Nonidet P-40 cell lysates were immunoprecipitated with antibody to SLAP-130 or SLP-76, and Western blots were probed with antibodies to VASP, SLAP-130, and SLP-76. Data shown are representative of three experiments.



    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The goal of this study was to determine how SLP-76 functions during alpha IIbbeta 3 signaling to influence cell shape and cytoskeletal organization. The study was motivated by recent observations that normal human and mouse platelets show increased tyrosine phosphorylation of SLP-76 in response to fibrinogen binding to alpha IIbbeta 3, suggesting that SLP-76 is involved in outside-in signaling through this integrin. Furthermore, mouse platelets deficient in SLP-76 spread poorly on fibrinogen and display reduced overall tyrosine phosphorylation, and both abnormalities are corrected by in vivo reconstitution of platelets with SLP-76 (23). Here we used a CHO cell model system and human platelets to evaluate the adapter functions of SLP-76 in the context of outside-in alpha IIbbeta 3 signaling. The main conclusions are as follows. 1) Ligation of alpha IIbbeta 3, whether with soluble or immobilized fibrinogen, induces rapid tyrosine phosphorylation of SLP-76 but only in the presence of Syk. 2) Integrin-dependent SLP-76 phosphorylation involves tyrosines 113, 128, 145 as well as other tyrosine residues in the protein. 3) Phosphorylation of SLP-76 does not require actin polymerization. Rather, SLP-76 expression enhances an actin-driven response, lamellipodia formation, that is triggered by a pathway involving alpha IIbbeta 3, Syk, Vav1, and Rac. 4) Whereas SLP-76 interacts with Vav1, enhancement of lamellipodia formation by SLP-76 is not because of increased tyrosine phosphorylation of Vav1 or activation of Rac. Instead, it may be because of interactions of SLP-76 with other proteins, including Nck and SLAP-130. For example, interaction of SLP-76 with Nck may account for the enhanced adhesion-dependent activation of PAK observed in SLP-76 transfectants. Furthermore, interaction of SLP-76 with SLAP-130 may promote localization of SLAP-130 and VASP to the periphery of fibrinogen-adherent platelets. Thus, SLP-76 functions to relay signals between alpha IIbbeta 3 and effectors that influence the actin cytoskeleton. In addition to defining a key pathway linking alpha IIbbeta 3 to changes in F-actin, these results provide a molecular explanation for the integrin phenotype of SLP-76-deficient platelets.

Integrin Signaling to SLP-76-- SLP-76 is one of numerous proteins that become tyrosine phosphorylated in response to ligand binding to alpha IIbbeta 3. These can be grouped based on their temporal profiles and whether actin polymerization is required (6). For example, Syk and Vav1 become phosphorylated within seconds of fibrinogen binding to alpha IIbbeta 3 in platelets or A5 CHO cells, and this response is independent of actin polymerization or cell aggregation (10, 27, 37). In contrast, FAK, Hic-5, SHIP, and the integrin beta 3 cytoplasmic tail become phosphorylated later, only after actin polymerization and cell aggregation or spreading have occurred (11, 41-45). The rapid tyrosine phosphorylation of SLP-76 after fibrinogen binding to platelets or A5 CHO cells and its resistance to cytochalasin D places SLP-76 in the group with Syk and Vav1. Indeed, the present study establishes that alpha IIbbeta 3-dependent SLP-76 phosphorylation requires Syk. Moreover, SLP-76 functions with Syk and Vav1 to enhance lamellipodia formation. Thus, SLP-76 is situated downstream of alpha IIbbeta 3 in an early phase of outside-in signaling.

Studies with SLP-76-(3Yright-arrowF), which lacks tyrosines 113, 128, and 145, clarify the importance of these residues in integrin signaling and suggest possible differences in SLP-76 function downstream of integrins and immune response receptors. These tyrosines are necessary for the binding of SLP-76 to the SH2 domains of Vav1 and Nck (Refs. 16, 46 and Figs. 1 and 4). In contrast to SLP-76 phosphorylation in response to T cell receptor ligation (46) or to overexpression of an ITAM-bearing CD8/gamma chimera in CHO cells, we observed residual tyrosine phosphorylation of SLP-76-(3Yright-arrowF) in response to fibrinogen binding to alpha IIbbeta 3 (Figs. 2C and 4). This indicates that one or more additional tyrosines in SLP-76 are targeted by a tyrosine kinase, possibly Syk, during alpha IIbbeta 3 signaling. However, the identity and function of these tyrosines remain to be determined.

In most T cells, a T cell-specific Src family kinase, Lck, and the Syk homologue, ZAP-70, are required for SLP-76 phosphorylation. In platelets and A5 CHO cells, Syk is the relevant ZAP-70 family member, and its optimal activation is dependent on one or more Src family kinases other than Lck (28, 47). Thus, differences in SLP-76 phosphorylation downstream of ITAM receptors and alpha IIbbeta 3 might be caused by, in part, differences in substrate specificities or subcellular localization of related, but not identical, protein tyrosine kinases. However, this cannot explain the differences we observed in SLP-76 phosphorylation downstream of alpha IIbbeta 3 and CD8/gamma in CHO cells because both membrane receptors utilized Syk in the same cellular background. Murine platelets express alpha IIbbeta 3 and the ITAM-bearing collagen receptor, GPVI/Fcgamma , and both are functionally linked to SLP-76 (47). Because retroviruses can be used to reconstitute SLP-76 in hematopoietic cells of SLP-76-/- mice (23), it should be possible to determine the functional importance of specific SLP-76 tyrosine residues downstream of alpha IIbbeta 3 and GPVI/Fcgamma by introducing SLP-76 tyrosine mutants into SLP-76-/- platelets.

Integrin Signaling from SLP-76 to the Actin Cytoskeleton-- The spreading defect in fibrinogen-adherent SLP-76-/- mouse platelets (23), and the involvement of SLP-76 in actin cap formation in antigen-activated T cells (16), suggest that one function for SLP-76 in platelets may be to relay alpha IIbbeta 3 signals to the cytoskeleton. This idea is supported by the current findings that SLP-76 phosphorylation occurred rapidly following A5 CHO cell adhesion to fibrinogen, and this response was independent of actin polymerization (Fig. 2B). Furthermore, SLP-76 expression in CHO cells enhanced lamellipodia formation, an event dependent on localized actin polymerization (Fig. 3B). Although caution is warranted in extrapolating results from studies of ectopically expressed SLP-76 in CHO cells to the function of SLP-76 in platelets, these results indicate that SLP-76 has the potential to participate in signaling from alpha IIbbeta 3 to the platelet cytoskeleton, and they provide an explanation for the spreading defect in SLP-76-/- platelets

How does SLP-76 enhance lamellipodia formation? One possibility we considered is that when tyrosine-phosphorylated SLP-76 binds to Vav1, it may promote either the guanine nucleotide exchange activity of Vav1 or its proximity to effectors, such as Rac. SLP-76 coimmunoprecipitates with Vav1 in activated T cells (16) and in collagen-stimulated platelets (47), implying that it may be close enough to Vav1 to directly influence its function. In addition, Vav1 can activate Rac and promote lamellipodia formation downstream of alpha IIbbeta 3 (Fig. 3B, Ref. 27). Despite this circumstantial evidence, however, we found that expression of SLP-76 in A5 cells affected neither the integrin-dependent tyrosine phosphorylation of Vav1, which regulates Vav1 exchange activity (13, 38, 39), nor the adhesion-dependent activation of Rac (Fig. 5A). Moreover, lamellipodia formation was still enhanced by SLP-76-(3Yright-arrowF), despite the fact that it was unable to coimmunoprecipitate with Vav1 (Figs. 3B and 4). Therefore, enhancement of lamellipodia formation by SLP-76 must involve pathways to the cytoskeleton that are downstream of and/or independent of Rac. Studies of PAK and VASP suggest that both possibilities may be correct.

PAK is a Rac effector that has been implicated in regulating actin polymerization, and it is targeted to integrin-based adhesion sites by binding to the central SH3 domain of Nck (17, 48). In this context, adhesion of A5 CHO cells to fibrinogen stimulated the binding of Nck to tyrosine-phosphorylated SLP-76 (Fig. 4). This was associated with an increase in the kinase activity of PAK that was over and above the activity observed in fibrinogen-adherent cells in the absence of SLP-76 (Fig. 6). Thus, one plausible scenario is that fibrinogen binding to alpha IIbbeta 3 triggers activation of Syk followed by tyrosine phosphorylation of SLP-76 and Vav1 in proximity to the integrin. Then whereas Vav1 activates Rac, SLP-76 recruits Nck-PAK to the adhesion site where PAK becomes activated by Rac, resulting in lamellipodia formation. However, this cannot explain how SLP-76-(3Yright-arrowF) enhanced lamellipodia formation in A5 CHO cells, because this mutant neither bound to Nck nor increased PAK activation (Figs. 4 and 6, B and C). Interestingly, mutation of other single adapter sites in SLP-76 for Gads or SLAP-130 also failed to prevent lamellipodial enhancement (Fig. 3B). We speculate that when a single adapter region in SLP-76 is mutated, the remaining regions may be able to compensate and promote cytoskeletal changes, particularly if the mutant protein is expressed at high levels, as in the CHO cell system. This interpretation is in keeping with the observation that deletion of larger portions of SLP-76 eliminated its ability to enhance lamellipodia formation (Fig. 3B). It may be useful to determine whether portions of SLP-76 not yet assigned an adapter function, including the SAM domain or phosphotyrosines other than those at positions 113, 128, and 145, are involved in signal relay from alpha IIbbeta 3 to actin.

VASP is an actin-bundling protein that regulates actin dynamics within lamellipodia, possibly by bringing the Arp2/3 actin polymerization machinery and profilin into proximity within integrin-based focal complexes (4, 49-52). VASP has the potential to interact directly with SLAP-130 in lymphocytes (22), where tyrosine-phosphorylated SLAP-130 interacts with SLP-76 (20, 53). Because VASP and SLAP-130 are expressed in platelets, this suggested to us a possible link between alpha IIbbeta 3, SLP-76, SLAP-130, and VASP. Indeed, we found that the adhesion of human platelets to fibrinogen was associated with 1) tyrosine phosphorylation of a pool of SLAP-130 that coimmunoprecipitated with SLP-76 (Fig. 7), 2) coprecipitation of SLAP-130 and SLP-76 with VASP (Fig. 8B), and 3) colocalization SLAP-130 and VASP at the platelet periphery (Fig. 8A). Interestingly, VASP-/- murine platelets exhibit increased fibrinogen binding in response to agonists, further suggesting a close functional relationship between VASP and alpha IIbbeta 3 (54, 55). Thus, further investigation is warranted into the role of a SLP-76·SLAP-130·VASP complex in alpha IIbbeta 3 signaling to the platelet cytoskeleton.

These studies, when taken together with recent results obtained with platelets from SLP-76 knockout mice (23), establish that SLP-76 relays signals from alpha IIbbeta 3 to actin by virtue of the regulated interaction of SLP-76 with multiple downstream effectors that modify the assembly and localization of actin filaments. This model does not require that a given SLP-76 molecule interact simultaneously with all possible binding partners in the relay, because many SLP-76 molecules could be drawn into a large signaling organelle nucleated by alpha IIbbeta 3 within focal complexes at sites of platelet adhesion. In this context, antibody-mediated clustering of integrin alpha 4beta 1 in lymphocytes stimulates tyrosine phosphorylation of SLP-76 and SLAP-130, and overexpression of SLAP-130 enhances lymphocyte migration through fibronectin-coated filters (56). Thus, delineation of the function of SLP-76 in platelet alpha IIbbeta 3 signaling may have wider implications for integrin signaling in other hematopoietic cells.


    ACKNOWLEDGEMENTS

We thank David Phillips (Cor Therapeutics, Inc., South San Francisco, CA) for providing Integrilin, Beat Steiner (Roche, Basel, Switzerland) for RO 43-5054, David Schlaepfer (Scripps) for the anti-Nck antibody, and Mark Ginsberg (Scripps) for the LIBS6 Fab.


    FOOTNOTES

* These studies were supported by research grants from the National Institutes of Health (to M. A. S., G. A. K., S. J. S) and postdoctoral fellowships from the Deutsche Forschungsgemeinschaft (to A. O.) and the Human Frontiers Science Program (to M. A. P).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

** To whom correspondence should be addressed: Dept. of Vascular Biology, The Scripps Research Inst., 10550 North Torrey Pines Rd., VB-5, La Jolla, CA 92037. Tel.: 858-784-7148; Fax: 858-784-7422; E-mail: shattil@scripps.edu.

Published, JBC Papers in Press, December 11, 2000, DOI 10.1074/jbc.M010639200


    ABBREVIATIONS

The abbreviations used are: ECM, extracellular matrix; BSA, bovine serum albumin; PMA, phorbol myristate acetate; RIPA, radioimmune precipitation assay buffer; CHO, Chinese hamster ovary cells; FAK, focal adhesion kinase.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES


1. Giancotti, F., and Ruoshlati, E. (1999) Science 285, 1028-1032[Abstract/Free Full Text]
2. Dedhar, S., and Hannigan, G. E. (1996) Curr. Opin. Cell Biol. 8, 657-669[CrossRef][Medline] [Order article via Infotrieve]
3. Hemler, M. E. (1998) Curr. Opin. Cell Biol. 10, 578-585[CrossRef][Medline] [Order article via Infotrieve]
4. Calderwood, D. A., Shattil, S. J., and Ginsberg, M. H. (2000) J. Biol. Chem. 275, 22607-22610[Free Full Text]
5. Pawson, T., and Scott, J. D. (1997) Science 278, 2075-2080[Abstract/Free Full Text]
6. Shattil, S. J., Kashiwagi, H., and Pampori, N. (1998) Blood 91, 2645-2657[Free Full Text]
7. Nachmias, V. T., and Golla, R. (1991) Cell Motil. Cytoskel. 20, 190-202[Medline] [Order article via Infotrieve]
8. Leng, L., Kashiwagi, H., Ren, X.-D., and Shattil, S. J. (1998) Blood 91, 4206-4215[Abstract/Free Full Text]
9. Yuan, Y. P., Kulkarni, S., Ulsemer, P., Cranmer, S. L., Yap, C. L., Nesbitt, W. S., Harper, I., Mistry, N., Dopheide, S. M., Hughan, S. C., Williamson, D., De la Salle, C., Salem, H. H., Lanza, F., and Jackson, S. P. (1999) J. Biol. Chem. 274, 36241-36251[Abstract/Free Full Text]
10. Clark, E. A., Shattil, S. J., Ginsberg, M. H., Bolen, J., and Brugge, J. S. (1994) J. Biol. Chem. 46, 28859-28864
11. Lipfert, L., Haimovich, B., Schaller, M. D., Cobb, B. S., Parsons, J. T., and Brugge, J. S. (1992) J. Cell Biol. 119, 905-912[Abstract]
12. Law, D. A., DeGuzman, F. R., Heiser, P., Ministri-Madrid, K., Killeen, N., and Phillips, D. R. (1999) Nature 401, 808-811[CrossRef][Medline] [Order article via Infotrieve]
13. Bustelo, X. R. (2000) Mol. Cell. Biol. 20, 1461-1477[Free Full Text]
14. Bishop, A. L., and Hall, A. (2000) Biochem. J. 348, 241-255[CrossRef][Medline] [Order article via Infotrieve]
15. Fang, N., Motto, D. G., Ross, S. E., and Koretzky, G. A. (1996) J. Immunol. 157, 3769-3773[Abstract]
16. Wardenburg, J. B., Pappu, R., Bu, J. Y., Mayer, B., Chernoff, J., Straus, D., and Chan, A. C. (1998) Immunity 9, 607-616[Medline] [Order article via Infotrieve]
17. Bagrodia, S., and Cerione, R. A. (1999) Trends Cell Biol 9, 350-355[CrossRef][Medline] [Order article via Infotrieve]
18. Liu, S. K., Fang, N., Koretzky, G. A., and McGlade, C. J. (1999) Curr. Biol. 9, 67-75[CrossRef][Medline] [Order article via Infotrieve]
19. da Silva, A. J., Li, Z., de Vera, C., Canto, E., Findell, P., and Rudd, C. E. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 7493-7498[Abstract/Free Full Text]
20. Musci, M. A., Hendricks-Taylor, L. R., Motto, D. G., Paskind, M., Kamens, J., Turck, C. W., and Koretzky, G. A. (1997) J. Biol. Chem. 272, 11674-11677[Abstract/Free Full Text]
21. Haffner, C., Jarchau, T., Reinhard, M., Hoppe, J., Lohmann, S. M., and Walter, U. (1995) EMBO J. 14, 19-27[Abstract]
22. Krause, M., Sechi, A. S., Konradt, M., Monner, D., Gertler, F. B., and Wehland, J. (2000) J. Cell Biol. 149, 181-194[Abstract/Free Full Text]
23. Judd, B. A., Myung, P. S., Leng, L., Obergfell, A., Pear, W. S., Shattil, S. J., and Koretzky, G. A. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 12056-12061[Abstract/Free Full Text]
24. Del Pozo, M. A., Price, L. S., Alderson, N. B., Ren, X. D., and Schwartz, M. A. (2000) EMBO J. 19, 2008-2014[Abstract/Free Full Text]
25. Motto, D. G., Ross, S. E., Wu, J., Hendricks-Taylor, L. R., and Koretzky, G. A. (1996) J. Exp. Med. 183, 1937-1943[Abstract]
26. O'Toole, T. E., Katagiri, Y., Faull, R. J., Peter, K., Tamura, R., Quaranta, V., Loftus, J. C., Shattil, S. J., and Ginsberg, M. H. (1994) J. Cell Biol. 124, 1047-1059[Abstract]
27. Miranti, C., Leng, L., Maschberger, P., Brugge, J. S., and Shattil, S. J. (1998) Curr. Biol. 8, 1289-1299[Medline] [Order article via Infotrieve]
28. Gao, J., Zoller, K., Ginsberg, M. H., Brugge, J. S., and Shattil, S. J. (1997) EMBO J. 16, 6414-6425[Abstract/Free Full Text]
29. Hato, T., Pampori, N., and Shattil, S. J. (1998) J. Cell Biol. 141, 1685-1695[Abstract/Free Full Text]
30. Alig, L., Edenhofer, A., Hadváry, P., Hürzeler, M., Knopp, D., Müller, M., Steiner, B., Trzeciak, A., and Weller, T. (1992) J. Med. Chem. 35, 4393-4407[Medline] [Order article via Infotrieve]
31. Haimovich, B., Lipfert, L., Brugge, J. S., and Shattil, S. J. (1993) J. Biol. Chem. 268, 15868-15877[Abstract/Free Full Text]
32. Bazzoni, G., and Hemler, M. E. (1998) Trends Biochem. Sci. 23, 30-34[CrossRef][Medline] [Order article via Infotrieve]
33. Hartwig, J. H. (1992) J. Cell Biol. 118, 1421-1442[Abstract]
34. Musci, M. A., Motto, D. G., Ross, S. E., Fang, N., and Koretzky, G. A. (1997) J. Immunol. 159, 1639-1647[Abstract]
35. Ridley, A. J., and Hall, A. (1992) Cold Spring Harbor Symp. Quant. Biol. 57, 661-672[Medline] [Order article via Infotrieve]
36. Hartwig, J. H., Bokoch, G. M., Carpenter, C. L., Janmey, P. A., Taylor, L. A., Toker, A., and Stossel, T. P. (1995) Cell 82, 643-653[Medline] [Order article via Infotrieve]
37. Cichowski, K., Brugge, J. S., and Brass, L. F. (1996) J. Biol. Chem. 271, 7544-7550[Abstract/Free Full Text]
38. Lopez-Lago, M., Lee, H., Cruz, C., Movilla, N., and Bustelo, X. R. (2000) Mol. Cell. Biol. 20, 1678-1691[Abstract/Free Full Text]
39. Aghazadeh, B., Lowry, W. E., Huang, X.-Y., and Rosen, M. K. (2000) Cell Adhes. Commun. 102, 625-633
40. Horstrup, K., Jablonka, B., Honig-Liedl, P., Just, M., Kochsiek, K., and Walter, U. (1994) Eur. J. Biochem. 225, 21-27[Abstract]
41. Leong, L., Hughes, P. E., Schwartz, M. A., Ginsberg, M. H., and Shattil, S. J. (1995) J. Cell Sci. 108, 3817-3825[Abstract/Free Full Text]
42. Law, D. A., Nannizzi-Alaimo, L., and Phillips, D. R. (1996) J. Biol. Chem. 271, 10811-10815[Abstract/Free Full Text]
43. Jackson, D. E., Ward, C. M., Wang, R. G., and Newman, P. J. (1997) J. Biol. Chem. 272, 6986-6993[Abstract/Free Full Text]
44. Giuriato, S., Payrastre, B., Drayer, A. L., Plantavid, M., Woscholski, R., Parker, P., Erneux, C., and Chap, H. (1997) J. Biol. Chem. 272, 26857-26863[Abstract/Free Full Text]
45. Hagmann, J., Grob, M., Welman, A., van Willigen, G., and Burger, M. M. (1998) J. Cell Sci. 111, 2181-2188[Abstract/Free Full Text]
46. Fang, N., and Koretzky, G. A. (1999) J. Biol. Chem. 274, 16206-16212[Abstract/Free Full Text]
47. Gross, B. S., Lee, J. R., Clements, J. L., Turner, M., Tybulewicz, V. L. J., Findell, P. R., Koretzky, G. A., and Watson, S. P. (1999) J. Biol. Chem. 274, 5963-5971[Abstract/Free Full Text]
48. Zhao, Z. S., Manser, E., and Lim, L. (2000) Mol. Cell. Biol. 20, 3906-3917[Abstract/Free Full Text]
49. Beckerle, M. C. (1998) Cell 95, 741-748[Medline] [Order article via Infotrieve]
50. Rottner, K., Behrendt, B., Small, J. V., and Wehland, J. (1999) Nat. Cell Biol. 1, 321-322[CrossRef][Medline] [Order article via Infotrieve]
51. Borisy, G. G., and Svitkina, T. M. (2000) Curr. Opin. Cell Biol. 12, 104-112[CrossRef][Medline] [Order article via Infotrieve]
52. Critchley, D. R. (2000) Curr. Opin. Cell Biol. 12, 133-139[CrossRef][Medline] [Order article via Infotrieve]
53. Raab, M., Kang, H., Da, Silva, A., Zhu, X. C., and Rudd, C. E. (1999) J. Biol. Chem. 274, 21170-21179[Abstract/Free Full Text]
54. Aszódi, A., Pfeifer, A., Ahmad, M., Glauner, M., Zhou, X. H., Ny, L., Andersson, K. E., Kehrel, B., Offermanns, S., and Fässler, R. (1999) EMBO J. 18, 37-48[Abstract/Free Full Text]
55. Hauser, W., Knobeloch, K. P., Eigenthaler, M., Gambaryan, S., Krenn, V., Geiger, J., Glazova, M., Rohde, E., Horak, I., Walter, U., and Zimmer, M. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 8120-8125[Abstract/Free Full Text]
56. Hunter, A. J., Ottoson, N., Boerth, N., Koretzky, G. A., and Shimizu, Y. (2000) J. Immunol. 164, 1143-1147[Abstract/Free Full Text]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.